Prothena (NASDAQ:PRTA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Prothena (NASDAQ:PRTA) released its earnings results on Thursday. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.06), Zacks reports. The company had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%.

Prothena Price Performance

Shares of NASDAQ:PRTA traded up $0.47 during midday trading on Friday, reaching $15.72. The company had a trading volume of 217,036 shares, compared to its average volume of 361,363. The stock has a market capitalization of $845.89 million, a P/E ratio of -6.32 and a beta of 0.08. The stock’s fifty day moving average price is $14.28 and its 200-day moving average price is $16.83. Prothena has a one year low of $11.70 and a one year high of $31.03.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Oppenheimer upped their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a report on Friday, February 7th. Chardan Capital restated a “buy” rating and issued a $40.00 price target on shares of Prothena in a report on Friday. Bank of America decreased their price target on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. StockNews.com lowered Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $48.00 target price on shares of Prothena in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.